Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCL NASDAQ:GPCR NASDAQ:LXEO NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.90-1.3%$4.54$1.89▼$6.41$1.76B0.695.29 million shs8.93 million shsGPCRStructure Therapeutics$27.28+2.5%$20.61$13.22▼$43.46$1.57B-1.651.06 million shs948,282 shsLXEOLexeo Therapeutics$6.62-1.2%$5.16$1.45▼$11.72$357.49M1.66790,301 shs448,657 shsSDGRSchrodinger$20.59-4.0%$19.61$16.60▼$28.47$1.52B1.741.09 million shs1.49 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%+24.47%+41.83%+55.06%+137.90%GPCRStructure Therapeutics0.00%+9.12%+38.06%+32.31%-37.27%LXEOLexeo Therapeutics0.00%-2.22%+33.20%+49.44%-24.08%SDGRSchrodinger0.00%+6.68%+8.54%-1.77%+15.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$5.90-1.3%$4.54$1.89▼$6.41$1.76B0.695.29 million shs8.93 million shsGPCRStructure Therapeutics$27.28+2.5%$20.61$13.22▼$43.46$1.57B-1.651.06 million shs948,282 shsLXEOLexeo Therapeutics$6.62-1.2%$5.16$1.45▼$11.72$357.49M1.66790,301 shs448,657 shsSDGRSchrodinger$20.59-4.0%$19.61$16.60▼$28.47$1.52B1.741.09 million shs1.49 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%+24.47%+41.83%+55.06%+137.90%GPCRStructure Therapeutics0.00%+9.12%+38.06%+32.31%-37.27%LXEOLexeo Therapeutics0.00%-2.22%+33.20%+49.44%-24.08%SDGRSchrodinger0.00%+6.68%+8.54%-1.77%+15.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.71Moderate Buy$8.0035.59% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$68.67151.71% UpsideLXEOLexeo Therapeutics 2.71Moderate Buy$15.33131.62% UpsideSDGRSchrodinger 2.38Hold$26.5729.05% UpsideCurrent Analyst Ratings BreakdownLatest LXEO, GPCR, SDGR, and ABCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$19.009/29/2025SDGRSchrodingerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/27/2025ABCLAbCellera BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025GPCRStructure TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LXEOLexeo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025SDGRSchrodingerWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/8/2025GPCRStructure TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/15/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $15.008/15/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$15.00 ➝ $9.00(Data available from 10/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$28.83M61.15N/AN/A$3.58 per share1.65GPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/ALXEOLexeo Therapeutics$650K549.97N/AN/A$3.53 per share1.88SDGRSchrodinger$207.54M7.30N/AN/A$5.78 per share3.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$162.86M-$0.55N/AN/AN/A-511.88%-16.17%-12.24%11/6/2025 (Confirmed)GPCRStructure Therapeutics-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)SDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)Latest LXEO, GPCR, SDGR, and ABCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025LXEOLexeo Therapeutics-$0.64-$0.60+$0.04-$0.60N/AN/A8/7/2025Q2 2025ABCLAbCellera Biologics-$0.17-$0.12+$0.05-$0.12$7.55 million$17.08 million8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/A8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A11.0711.07GPCRStructure TherapeuticsN/A20.4820.48LXEOLexeo TherapeuticsN/A4.434.43SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%GPCRStructure Therapeutics91.78%LXEOLexeo Therapeutics60.67%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%GPCRStructure Therapeutics5.60%LXEOLexeo Therapeutics5.30%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.83 million212.47 millionOptionableGPCRStructure Therapeutics13657.60 million54.37 millionOptionableLXEOLexeo Therapeutics5854.00 million51.14 millionNot OptionableSDGRSchrodinger79073.61 million58.15 millionOptionableLXEO, GPCR, SDGR, and ABCL HeadlinesRecent News About These CompaniesCraig-Hallum Keeps Their Buy Rating on Schrodinger (SDGR)October 4 at 9:47 PM | theglobeandmail.comSchrodinger (NASDAQ:SDGR) Downgraded to "Sell" Rating by Wall Street ZenOctober 4 at 3:09 AM | marketbeat.comSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Rating of "Hold" by AnalystsOctober 4 at 2:39 AM | marketbeat.comSchrodinger (NASDAQ:SDGR) Trading Down 3.6% - Here's WhyOctober 3 at 8:13 PM | marketbeat.comGoldman Sachs Initiates Coverage of Schrödinger (SDGR) with Neutral RecommendationOctober 1, 2025 | msn.comSchrodinger (NASDAQ:SDGR) Stock Rating Upgraded by The Goldman Sachs GroupOctober 1, 2025 | marketbeat.comPerigon Wealth Management LLC Purchases Shares of 14,636 Schrodinger, Inc. $SDGROctober 1, 2025 | marketbeat.comExpert Outlook: Schrodinger Through The Eyes Of 5 AnalystsOctober 1, 2025 | benzinga.comSchrodinger initiated with a Neutral at Goldman SachsSeptember 29, 2025 | msn.comSchrodinger (NASDAQ:SDGR) Rating Increased to Hold at Wall Street ZenSeptember 27, 2025 | americanbankingnews.comWall Street Zen Upgrades Schrodinger (NASDAQ:SDGR) to "Hold"September 26, 2025 | marketbeat.comCareview Communications (OTCMKTS:CRVW) & Schrodinger (NASDAQ:SDGR) Head-To-Head ReviewSeptember 26, 2025 | americanbankingnews.comSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 18, 2025 | businesswire.comGoldman Sachs Group Inc. Sells 103,348 Shares of Schrodinger, Inc. $SDGRSeptember 16, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Buys 2,737,728 Shares of Schrodinger, Inc. $SDGRSeptember 15, 2025 | marketbeat.comGeneos Wealth Management Inc. Boosts Position in Schrodinger, Inc. $SDGRSeptember 14, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Stock Price Down 5.9% - Should You Sell?September 12, 2025 | marketbeat.comJones Financial Companies Lllp Increases Stock Position in Schrodinger, Inc. $SDGRSeptember 12, 2025 | marketbeat.comSchrödinger (SDGR): Evaluating Valuation as Market Sentiment Remains QuietSeptember 11, 2025 | finance.yahoo.comSchrodinger, Inc. (NASDAQ:SDGR) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 10, 2025 | marketbeat.comDoes Schrodinger (SDGR) Have the Potential to Rally 40.43% as Wall Street Analysts Expect?September 9, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXEO, GPCR, SDGR, and ABCL Company DescriptionsAbCellera Biologics NASDAQ:ABCL$5.90 -0.08 (-1.34%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.40 +0.50 (+8.47%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.Structure Therapeutics NASDAQ:GPCR$27.28 +0.66 (+2.48%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$26.58 -0.71 (-2.58%) As of 10/3/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Lexeo Therapeutics NASDAQ:LXEO$6.62 -0.08 (-1.19%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.59 -0.03 (-0.44%) As of 10/3/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.Schrodinger NASDAQ:SDGR$20.59 -0.86 (-4.01%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$20.70 +0.11 (+0.53%) As of 10/3/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
